AIMS/HYPOTHESIS: Type 1 diabetes in children is characterised by autoimmune destruction of pancreatic beta cells and the presence of certain risk genotypes. In adults the same situation is often referred to as latent autoimmune diabetes in adults (LADA). We tested whether genetic markers associated with type 1 or type 2 diabetes could help to discriminate between autoimmune and non-autoimmune diabetes in young (15-34 years) and middle-aged (40-59 years) diabetic patients. METHODS: In 1,642 young and 1,619 middle-aged patients we determined: (1) HLA-DQB1 genotypes; (2) PTPN22 and INS variable-number tandem repeat (VNTR) polymorphisms; (3) two single nucleotide polymorphisms (rs7903146 and rs10885406) in the TCF7L2 gene; (4) glutamic acid decarboxylase (GAD) and IA-2-protein tyrosine phosphatase-like protein (IA-2) antibodies; and (5) fasting plasma C-peptide. RESULTS: Frequency of risk genotypes HLA-DQB1 (60% vs 25%, p = 9.4 x 10(-34); 45% vs 18%, p = 1.4 x 10(-16)), PTPN22 CT/TT (34% vs 26%, p = 0.0023; 31% vs 23%, p = 0.034), INS VNTR class I/I (69% vs 53%, p = 1.3 x 10(-8); 69% vs 51%, p = 8.5 x 10(-5)) and INS VNTR class IIIA/IIIA (75% vs 63%, p = 4.3 x 10(-6); 73% vs 60%, p = 0.008) was increased in young and middle-aged GAD antibodies (GADA)-positive compared with GADA-negative patients. The type 2 diabetes-associated genotypes of TCF7L2 CT/TT of rs7903146 were significantly more common in young GADA-negative than in GADA-positive patients (53% vs 43%; p = 0.0004). No such difference was seen in middle-aged patients, in whom the frequency of the CT/TT genotypes of TCF7L2 was similarly increased in GADA-negative and GADA-positive groups (55% vs 56%). CONCLUSIONS/ INTERPRETATION: Common variants in the TCF7L2 gene help to differentiate young but not middle-aged GADA-positive and GADA-negative diabetic patients, suggesting that young GADA-negative patients have type 2 diabetes and that middle-aged GADA-positive patients are different from their young GADA-positive counterparts and share genetic features with type 2 diabetes.
AIMS/HYPOTHESIS: Type 1 diabetes in children is characterised by autoimmune destruction of pancreatic beta cells and the presence of certain risk genotypes. In adults the same situation is often referred to as latent autoimmune diabetes in adults (LADA). We tested whether genetic markers associated with type 1 or type 2 diabetes could help to discriminate between autoimmune and non-autoimmune diabetes in young (15-34 years) and middle-aged (40-59 years) diabeticpatients. METHODS: In 1,642 young and 1,619 middle-aged patients we determined: (1) HLA-DQB1 genotypes; (2) PTPN22 and INS variable-number tandem repeat (VNTR) polymorphisms; (3) two single nucleotide polymorphisms (rs7903146 and rs10885406) in the TCF7L2 gene; (4) glutamic acid decarboxylase (GAD) and IA-2-protein tyrosine phosphatase-like protein (IA-2) antibodies; and (5) fasting plasma C-peptide. RESULTS: Frequency of risk genotypes HLA-DQB1 (60% vs 25%, p = 9.4 x 10(-34); 45% vs 18%, p = 1.4 x 10(-16)), PTPN22 CT/TT (34% vs 26%, p = 0.0023; 31% vs 23%, p = 0.034), INS VNTR class I/I (69% vs 53%, p = 1.3 x 10(-8); 69% vs 51%, p = 8.5 x 10(-5)) and INS VNTR class IIIA/IIIA (75% vs 63%, p = 4.3 x 10(-6); 73% vs 60%, p = 0.008) was increased in young and middle-aged GAD antibodies (GADA)-positive compared with GADA-negative patients. The type 2 diabetes-associated genotypes of TCF7L2 CT/TT of rs7903146 were significantly more common in young GADA-negative than in GADA-positive patients (53% vs 43%; p = 0.0004). No such difference was seen in middle-aged patients, in whom the frequency of the CT/TT genotypes of TCF7L2 was similarly increased in GADA-negative and GADA-positive groups (55% vs 56%). CONCLUSIONS/ INTERPRETATION: Common variants in the TCF7L2 gene help to differentiate young but not middle-aged GADA-positive and GADA-negative diabeticpatients, suggesting that young GADA-negative patients have type 2 diabetes and that middle-aged GADA-positive patients are different from their young GADA-positive counterparts and share genetic features with type 2 diabetes.
Authors: E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist Journal: Diabetologia Date: 2006-05-31 Impact factor: 10.122
Authors: Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Agnes Vatay; Katalin Rajczy; Eva Pozsonyi; Nóra Hosszúfalusi; Zoltán Prohászka; George Füst; István Karádi; Csaba Szalai; Andrea Grósz; Zoltán Bártfai; Pál Pánczél Journal: Immunol Lett Date: 2002-11-01 Impact factor: 3.685
Authors: Gunnar Stenström; Bo Berger; Henrik Borg; Per Fernlund; Janice S Dorman; Göran Sundkvist Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Eleftheria Zeggini; Michael N Weedon; Cecilia M Lindgren; Timothy M Frayling; Katherine S Elliott; Hana Lango; Nicholas J Timpson; John R B Perry; Nigel W Rayner; Rachel M Freathy; Jeffrey C Barrett; Beverley Shields; Andrew P Morris; Sian Ellard; Christopher J Groves; Lorna W Harries; Jonathan L Marchini; Katharine R Owen; Beatrice Knight; Lon R Cardon; Mark Walker; Graham A Hitman; Andrew D Morris; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Maria J Redondo; Jesse Muniz; Luisa M Rodriguez; Dinakar Iyer; Fariba Vaziri-Sani; Morey W Haymond; Christiane S Hampe; Michael L Metzker; Struan F A Grant; Ashok Balasubramanyam Journal: BMJ Open Diabetes Res Care Date: 2014-04-06
Authors: Virve M Lundgren; Bo Isomaa; Valeriya Lyssenko; Esa Laurila; Pasi Korhonen; Leif C Groop; Tiinamaija Tuomi Journal: Diabetes Date: 2009-10-28 Impact factor: 9.461
Authors: Benjamin F Voight; Hyun Min Kang; Jun Ding; Cameron D Palmer; Carlo Sidore; Peter S Chines; Noël P Burtt; Christian Fuchsberger; Yanming Li; Jeanette Erdmann; Timothy M Frayling; Iris M Heid; Anne U Jackson; Toby Johnson; Tuomas O Kilpeläinen; Cecilia M Lindgren; Andrew P Morris; Inga Prokopenko; Joshua C Randall; Richa Saxena; Nicole Soranzo; Elizabeth K Speliotes; Tanya M Teslovich; Eleanor Wheeler; Jared Maguire; Melissa Parkin; Simon Potter; N William Rayner; Neil Robertson; Kathleen Stirrups; Wendy Winckler; Serena Sanna; Antonella Mulas; Ramaiah Nagaraja; Francesco Cucca; Inês Barroso; Panos Deloukas; Ruth J F Loos; Sekar Kathiresan; Patricia B Munroe; Christopher Newton-Cheh; Arne Pfeufer; Nilesh J Samani; Heribert Schunkert; Joel N Hirschhorn; David Altshuler; Mark I McCarthy; Gonçalo R Abecasis; Michael Boehnke Journal: PLoS Genet Date: 2012-08-02 Impact factor: 5.917
Authors: Maria J Redondo; Susan Geyer; Andrea K Steck; Jay Sosenko; Mark Anderson; Peter Antinozzi; Aaron Michels; John Wentworth; Ping Xu; Alberto Pugliese Journal: Diabetes Care Date: 2017-10-12 Impact factor: 19.112
Authors: Diana L Cousminer; Emma Ahlqvist; Rajashree Mishra; Mette K Andersen; Alessandra Chesi; Mohammad I Hawa; Asa Davis; Kenyaita M Hodge; Jonathan P Bradfield; Kaixin Zhou; Vanessa C Guy; Mikael Åkerlund; Mette Wod; Lars G Fritsche; Henrik Vestergaard; James Snyder; Kurt Højlund; Allan Linneberg; Annemari Käräjämäki; Ivan Brandslund; Cecilia E Kim; Daniel Witte; Elin Pettersen Sørgjerd; David J Brillon; Oluf Pedersen; Henning Beck-Nielsen; Niels Grarup; Richard E Pratley; Michael R Rickels; Adrian Vella; Fernando Ovalle; Olle Melander; Ronald I Harris; Stephen Varvel; Valdemar E R Grill; Hakon Hakonarson; Philippe Froguel; John T Lonsdale; Didac Mauricio; Nanette C Schloot; Kamlesh Khunti; Carla J Greenbaum; Bjørn Olav Åsvold; Knud B Yderstræde; Ewan R Pearson; Stanley Schwartz; Benjamin F Voight; Torben Hansen; Tiinamaija Tuomi; Bernhard O Boehm; Leif Groop; R David Leslie; Struan F A Grant Journal: Diabetes Care Date: 2018-09-25 Impact factor: 19.112